MVAL - ETF AI Analysis
Top Page
VanEck Morningstar Wide Moat Value ETF (MVAL)
Rating:70Neutral
Price Target:―
Positive Factors
Resilient Consumer Defensive Focus
A large share of the fund is in consumer defensive companies, which tend to hold up better during economic slowdowns.
Several Strong Top Holdings
Some of the biggest positions, such as Constellation Brands, Brown-Forman, Bristol-Myers Squibb, and NXP Semiconductors, have shown strong year-to-date performance, helping support the ETF’s returns.
Broad Sector Mix Within Value Stocks
Exposure to health care, industrials, technology, financials, and materials adds diversification across different parts of the economy within a value-focused strategy.
Negative Factors
Heavy U.S. Concentration
Almost all assets are invested in U.S. companies, so the fund offers little geographic diversification if the U.S. market struggles.
Notable Lagging Holdings
Several meaningful positions, including Danaher and Campbell Soup, have shown weak year-to-date performance, which can drag on overall returns.
Moderate Expense Ratio
The fund’s expense ratio is not especially low, so fees may be higher than some broad, low-cost index ETFs.
MVAL vs. SPDR S&P 500 ETF (SPY)
AUM1.87M
RegionNorth America
Expense Ratio0.50%
Beta0.71
IssuerVanEck
Inception DateMar 26, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedMorningstar US Broad Value Wide Moat Focus Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,624
30 Day Avg. Volume735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.49Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering45
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MVAL Summary
The VanEck Morningstar Wide Moat Value ETF (MVAL) tracks the Morningstar US Broad Value Wide Moat Focus Index, which looks for U.S. companies that are considered undervalued and have strong, lasting competitive advantages. It holds a mix of defensive, health care, industrial, and tech names, including well-known companies like United Parcel Service (UPS), Clorox, and Campbell Soup. Someone might invest in MVAL to seek long-term growth from high-quality value stocks while staying diversified across sectors. A key risk is that value stocks can stay out of favor for long periods, and the share price can still go up and down with the overall market.
How much will it cost me?The VanEck Morningstar Wide Moat Value ETF (MVAL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on selecting companies with strong competitive advantages. Active management typically involves more research and analysis, which can lead to higher costs.
What would affect this ETF?The VanEck Morningstar Wide Moat Value ETF (MVAL) could benefit from long-term growth in sectors like Health Care and Consumer Defensive, which are its largest exposures and tend to perform well during economic uncertainty. However, rising interest rates or economic slowdowns could negatively impact industrial and cyclical sectors, which also make up a significant portion of the ETF's holdings. Regulatory changes or competitive pressures affecting top holdings like Thermo Fisher or Nike may also influence the ETF's performance.
MVAL Top 10 Holdings
MVAL leans heavily on defensive U.S. names, with consumer staples and health care acting as the fund’s backbone. Brown-Forman and Kenvue have been quietly rising, giving the ETF a steady lift, while home-improvement player Masco has been a bright spot with more upbeat momentum. On the flip side, medical names like Danaher and Zimmer Biomet have been mixed, and Nike has been losing steam, dragging on returns. Overall, the fund is concentrated in wide-moat, U.S.-based defensives, trading some short-term sizzle for long-term resilience.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Kenvue, Inc. | 4.72% | $89.04K | $38.07B | -6.41% | 73 Outperform | |
| Danaher | 4.35% | $82.09K | $140.09B | -3.23% | 75 Outperform | |
| Brown-Forman B | 4.29% | $80.93K | $12.10B | -9.55% | 74 Outperform | |
| Zimmer Biomet Holdings | 4.27% | $80.51K | $16.92B | -3.04% | 73 Outperform | |
| Bristol-Myers Squibb | 4.25% | $80.17K | $118.71B | 23.24% | 78 Outperform | |
| Clorox | 4.00% | $75.37K | $11.76B | -22.66% | 55 Neutral | |
| Constellation Brands | 3.87% | $72.92K | $23.48B | -22.74% | 67 Neutral | |
| GE Healthcare Technologies Inc | 3.50% | $66.01K | $29.82B | -13.78% | 78 Outperform | |
| Masco | 3.08% | $58.02K | $16.70B | 21.04% | 53 Neutral | |
| Nike | 3.06% | $57.73K | $65.29B | -41.54% | 61 Neutral |
MVAL Technical Analysis
Positive
―
Price Trends
36.03
Positive
36.53
Positive
36.15
Positive
Market Momentum
0.33
Negative
61.05
Neutral
89.78
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.50, equal to the 50-day MA of 36.03, and equal to the 200-day MA of 36.15, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 61.05 is Neutral, neither overbought nor oversold. The STOCH value of 89.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MVAL.
MVAL Peer Comparison
Comparison Results
Performance Comparison
MVAL
VanEck Morningstar Wide Moat Value ETF
37.28
4.46
13.59%
GMOV
GMO US Value ETF
―
―
―
SASS
M.D. Sass Concentrated Value ETF
―
―
―
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
RAUS
RACWI US ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents